17:21 EDT Regenxbio (RGNX) files to sell 268,096 shares of common stock for holders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
- Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
- RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
- Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial
- RegenXBio Holds 2025 Annual Stockholders Meeting